Resumen de acción B6E Swedish Orphan Biovitrum AB (publ), empresa biotecnológica integrada, investiga, desarrolla, fabrica y vende productos farmacéuticos en las áreas terapéuticas de hematología, inmunología y cuidados especializados en Europa, Norteamérica, Oriente Medio, Asia y Australia. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Swedish Orphan Biovitrum AB (publ) Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Swedish Orphan Biovitrum Precios históricos de las acciones Precio actual de la acción SEK 26.86 Máximo en las últimas 52 semanas SEK 30.50 Mínimo de 52 semanas SEK 21.54 Beta 0.24 Cambio en 1 mes 6.67% Variación en 3 meses -4.95% Cambio de 1 año 12.67% Variación en 3 años 48.15% Variación en 5 años 81.61% Variación desde la OPV 125.71%
Noticias y actualizaciones recientes
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Third quarter 2024 earnings released: EPS: kr4.27 (vs kr0.30 in 3Q 2023) Oct 24 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025 Ver más actualizaciones
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Third quarter 2024 earnings released: EPS: kr4.27 (vs kr0.30 in 3Q 2023) Oct 24 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
General Counsel & Head of Legal Affairs recently sold €2.4m worth of stock Sep 02
Investor sentiment improves as stock rises 16% Aug 20
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
CEO & President recently sold €2.5m worth of stock Jul 29
Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct Jul 19
Second quarter 2024 earnings released: EPS: kr0.66 (vs kr0.71 in 2Q 2023) Jul 17 Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 16
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout Jul 02
European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A Jun 20
Head of North America recently sold €3.3m worth of stock Jun 10
CEO & President recently sold €2.6m worth of stock Jun 03
Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member May 15
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024 Apr 28 Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025
Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022) Apr 03
Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024 Feb 29
Head of Technical Operations recently sold €501k worth of stock Feb 15
Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022) Feb 09
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member Jan 05
Senior Scientific & Medical Advisor recently sold €1.4m worth of stock Nov 17
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024 Oct 31
Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022) Oct 31
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G Oct 18
Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer Oct 05 Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A Sep 25
Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 20
Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024
New major risk - Financial position Jul 19
Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022) Jul 19
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders. Jun 27
European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A May 19
Independent Chairman recently bought €1.0m worth of stock May 17
Less than half of directors are independent May 14 Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion. May 11
Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board May 10
Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021) Apr 08
Insider recently sold €1.2m worth of stock Mar 09
Head of Europe recently sold €1.4m worth of stock Mar 01
CEO & President recently sold €2.2m worth of stock Feb 17
Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021) Feb 09
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes Feb 03
ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine) Dec 21
Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia Nov 11
Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023 Nov 01 Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023
Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021) Oct 28
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Sep 17
Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa Aug 30
Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021) Jul 20
Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022 Jul 20
Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress Jun 10
Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need Jun 08
FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi Jun 01
Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member May 12
First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021) May 01
Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study Mar 10
Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH) Feb 26
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022 Feb 01
Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia Dec 18 Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population Dec 15
Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others. Dec 05
Investor sentiment deteriorated over the past week Dec 04
Head of Technical Operations recently bought €134k worth of stock Nov 23
Third quarter 2021 earnings released: EPS kr1.60 (vs kr0.94 in 3Q 2020) Oct 23
Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia Sep 08
Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia Sep 04
Investor sentiment improved over the past week Sep 03
Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover Aug 27
Second quarter 2021 earnings released: EPS kr0.91 (vs kr0.96 in 2Q 2020) Jul 22
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH May 26
CEO & President recently bought €805k worth of stock May 26
Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery May 21
CEO & President recently bought €419k worth of stock May 13
Director has left the company May 11 Rentabilidad de los accionistas B6E DE Biotechs Mercado DE 7D -3.2% -2.6% -2.0% 1Y 12.7% -13.2% 6.8%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: B6E superó a la industria German Biotechs, que obtuvo un rendimiento del -13.2% el año pasado.
Rentabilidad vs. Mercado: B6E superó al mercado German, que obtuvo un rendimiento del 6.8% el año pasado.
Volatilidad de los precios Is B6E's price volatile compared to industry and market? B6E volatility B6E Average Weekly Movement 5.2% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: B6E no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de B6E (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Fundada Empleados CEO Página web 1939 1,814 Guido Oelkers www.sobi.com
Swedish Orphan Biovitrum AB (publ), empresa biotecnológica integrada, investiga, desarrolla, fabrica y vende productos farmacéuticos en las áreas terapéuticas de hematología, inmunología y atención especializada en Europa, Norteamérica, Oriente Medio, Asia y Australia. Ofrece Alprolix para la hemofilia B; Aspaveli®/Empaveli para el tratamiento de pacientes adultos con hemoglobinuria paroxística nocturna; Doptelet para el tratamiento de la trombocitopenia; Elocta para la hemofilia A; Gamifant para la linfohistiocitosis hemofagocítica (HLH); VONJO para el tratamiento de adultos con mielofibrosis primaria o secundaria (post-policitemia vera o post-trombocitemia esencial) de riesgo intermedio o alto; Zynlonta, una enfermedad maligna agresiva; Kineret para el síndrome periódico asociado a la criopirina, la artritis reumatoide y la enfermedad de Still; Orfadin para tratar la tirosinemia hereditaria de tipo 1; y Synagis para infecciones graves de las vías respiratorias bajas. La empresa también suministra otros productos, como Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi y Waylivra.
Mostrar más Resumen de fundamentos de Swedish Orphan Biovitrum AB (publ) ¿Cómo se comparan los beneficios e ingresos de Swedish Orphan Biovitrum con su capitalización de mercado? Estadísticas fundamentales de B6E Capitalización bursátil €9.29b Beneficios(TTM ) €305.68m Ingresos (TTM ) €2.21b
30.4x Ratio precio-beneficio (PE)
4.2x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de B6E Ingresos SEK 25.44b Coste de los ingresos SEK 5.44b Beneficio bruto SEK 19.99b Otros gastos SEK 16.48b Beneficios SEK 3.51b
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
Feb 05, 2025
Beneficios por acción (BPA) 10.23 Margen bruto 78.60% Margen de beneficio neto 13.82% Ratio deuda/patrimonio 47.1%
¿Cómo se ha desempeñado B6E a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/23 18:18 Precio de las acciones al final del día 2024/12/23 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Swedish Orphan Biovitrum AB (publ) está cubierta por 29 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Alexander Lindström ABG Sundal Collier Rosie Turner Barclays Brian Balchin Barclays
Mostrar 26 más analistas 
